Table of Contents 1 Key Insights 2 Neurofibroma Market Overview at a Glance 2.1 Market Share (%) Distribution of Neurofibroma in 2018 2.2 Market Share (%) Distribution of Neurofibroma in 2028 3 Neurofibroma: Disease Background and Overview 3.1 Introduction 3.2 Symptoms 3.3 Etiology 3.4 Risk Factor 3.5 Pathophysiology 3.6 Diagnosis 3.7 Treatment 4 Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Neurofibroma in 7MM 4.3. Total Prevalent Patient Population of Neurofibroma in 7MM – By Countries 5 Epidemiology of Neurofibroma by Countries (2016-2028) 5.1 United States- Epidemiology (2016-2028) 5.1.1 Assumptions and Rationale 5.1.2 Prevalent/Incident Cases of Neurofibroma in the United States 5.1.3 Sub-Type Specific cases of Neurofibroma in the United States 5.1.4 Sex- Specific Cases of Neurofibroma in the United States 5.1.5 Diagnosed Cases of Neurofibroma in the United States 5.1.6 Treatable Cases of Neurofibroma in the United States 5.2 EU5 Countries 5.2.1 Germany 5.2.1.1 Assumptions and Rationale 5.2.1.2 Prevalent/Incident Cases of the of Neurofibroma in the Germany 5.2.1.3 Sub-Type Specific cases of Neurofibroma in the Germany 5.2.1.4 Sex- Specific Cases of the Neurofibroma in the Germany 5.2.1.5 Diagnosed Cases of the Neurofibroma in the Germany 5.2.1.6 Treatable Cases of the Neurofibroma 5.2.2 France 5.2.2.1 Assumptions and Rationale 5.2.2.2 Prevalent/Incident Cases of the of Neurofibroma in the France 5.2.2.3 Sub-Type Specific cases of Neurofibroma in the France 5.2.2.4 Sex- Specific Cases of the Neurofibroma in the France 5.2.2.5 Diagnosed Cases of the Neurofibroma in the France 5.2.2.6 Treatable Cases of the Neurofibroma 5.2.3 Italy 5.2.3.1 Assumptions and Rationale 5.2.3.2 Prevalent/Incident Cases of the of Neurofibroma in the Italy 5.2.3.3 Sub-Type Specific cases of Neurofibroma in the Italy 5.2.3.4 Sex- Specific Cases of the Neurofibroma in the Italy 5.2.3.5 Diagnosed Cases of the Neurofibroma in the Italy 5.2.3.6 Treatable Cases of the Neurofibroma 5.2.4 Spain 5.2.4.1 Assumptions and Rationale 5.2.4.2 Prevalent/Incident Cases of the of Neurofibroma in the Spain 5.2.4.3 Sub-Type Specific cases of Neurofibroma in the Spain 5.2.4.4 Sex- Specific Cases of the Neurofibroma in the Spain 5.2.4.5 Diagnosed Cases of the Neurofibroma in the Spain 5.2.4.6 Treatable Cases of the Neurofibroma 5.2.5 United Kingdom 5.2.5.1 Assumptions and Rationale 5.2.5.2 Prevalent/Incident Cases of the of Neurofibroma in the United Kingdom 5.2.5.3 Sub-Type Specific cases of Neurofibroma in the United Kingdom 5.2.5.4 Sex- Specific Cases of the Neurofibroma in the United Kingdom 5.2.5.5 Diagnosed Cases of the Neurofibroma in the United Kingdom 5.2.5.6 Treatable Cases of the Neurofibroma 5.3 Japan 5.3.1 Assumptions and Rationale 5.3.2 Prevalent/Incident Cases of the of Neurofibroma in the Japan 5.3.3 Sub-Type Specific cases of Neurofibroma in the Japan 5.3.4 Sex- Specific Cases of the Neurofibroma in the Japan 5.3.5 Diagnosed Cases of the Neurofibroma in the Japan 5.3.6 Treatable Cases of the Neurofibroma 6 Current Treatment & Medical practices 6.1 Treatment Algorithm 6.2 Treatment Guidelines 7 Unmet Needs 8 Marketed Product 8.1 Drug A: Company 1 8.1.1 Drug Description 8.1.2 Mechanism of Action 8.1.3 Clinical Trials Details 8.1.4 Advantages & Disadvantages 8.1.5 Safety and Efficacy 8.1.6 Product Profile 8.2 Drug B: Company 2 8.2.1 Drug Description 8.2.2 Mechanism of Action 8.2.3 Clinical Trials Details 8.2.4 Advantages & Disadvantages 8.2.5 Safety and Efficacy 8.2.6 Product Profile 8.3 Drug C: Company 3 8.3.1 Drug Description 8.3.2 Mechanism of Action 8.3.3 Clinical Trials Details 8.3.4 Advantages & Disadvantages 8.3.5 Safety and Efficacy 8.3.6 Product Profile 8.4 Drug D: Company 4 8.4.1 Drug Description 8.4.2 Mechanism of Action 8.4.3 Clinical Trials Details 8.4.4 Advantages & Disadvantages 8.4.5 Safety and Efficacy 8.4.6 Product Profile 8.5 Drug E: Company 5 8.5.1 Drug Description 8.5.2 Mechanism of Action 8.5.3 Clinical Trials Details 8.5.4 Advantages & Disadvantages 8.5.5 Safety and Efficacy 8.5.6 Product Profile 8.6 : Company 6 8.6.1 Drug Description 8.6.2 Mechanism of Action 8.6.3 Clinical Trials Details 8.6.4 Advantages & Disadvantages 8.6.5 Safety and Efficacy 8.6.6 Product Profile 8.7 : Company 7 8.7.1 Drug Description 8.7.2 Mechanism of Action 8.7.3 Clinical Trials Details 8.7.4 Advantages & Disadvantages 8.7.5 Safety and Efficacy 8.7.6 Product Profile 8.8 : Company 8 8.8.1 Drug Description 8.8.2 Mechanism of Action 8.8.3 Clinical Trials Details 8.8.4 Advantages & Disadvantages 8.8.5 Safety and Efficacy 8.8.6 Product Profile 9 Emerging Drugs 9.1 Key Cross Competition 9.2 Emerging company 9.2.1 Emerging Drug A: Company 12 9.2.1.1 Other Development Activities 9.2.1.2 Clinical Development 9.2.1.3 Clinical Trials Information 9.2.1.4 Safety and Efficacy 9.2.1.5 Advantages and Disadvantages 9.2.1.6 Product Profile 9.2.2 Emerging Drug B: Company 13 9.2.2.1 Other Development Activities 9.2.2.2 Clinical Development 9.2.2.3 Clinical Trials Information 9.2.2.4 Safety and Efficacy 9.2.2.5 Advantages and Disadvantages 9.2.2.6 Product Profile 9.2.3 Emerging Drug C: Company 14 9.2.3.1 Other Development Activities 9.2.3.2 Clinical Development 9.2.3.3 Clinical Trials Information 9.2.3.4 Safety and Efficacy 9.2.3.5 Advantages and Disadvantages 9.2.3.6 Product Profile 9.2.4 Emerging Drug D: Company 15 9.2.4.1 Other Development Activities 9.2.4.2 Clinical Development 9.2.4.3 Clinical Trials Information 9.2.4.4 Safety and Efficacy 9.2.4.5 Advantages and Disadvantages 9.2.4.6 Product Profile 9.2.5 Emerging Drug E: Company 16 9.2.5.1 Other Development Activities 9.2.5.2 Clinical Development 9.2.5.3 Clinical Trials Information 9.2.5.4 Safety and Efficacy 9.2.5.5 Advantages and Disadvantages 9.2.5.6 Product Profile 10 7MM Market Analysis 10.1 7MM Market Size of Neurofibroma 10.2 7MM Percentage Share of Drugs Marketed for Neurofibroma 10.3 7MM Market Sales of Neurofibroma by Products 11 The United States Market Outlook 11.1 Market Size of Neurofibroma in United States 11.2 Percentage Share of Drugs Marketed for Neurofibroma in United States 11.3 Market Sales of Neurofibroma by Products in United States 11.4 Analysis of Upcoming Therapies and Impact on the Market 12 EU5 Countries Market Outlook 12.1 Market Size of Neurofibroma in EU5 12.2 Market Size of Neurofibroma in Germany 12.2.1 Market Size of Neurofibroma in Germany 12.2.2 Percentage Share of Drugs Marketed for Neurofibroma in Germany 12.2.3 Market Sales of Neurofibroma by Products in Germany 12.2.4 Analysis of Upcoming Therapies and Impact on the Market 12.3 Market Size of Neurofibroma in France 12.3.1 Market Size of Neurofibroma in France 12.3.2 Percentage Share of Drugs Marketed for Neurofibroma in France 12.3.3 Market Sales of Neurofibroma by Products in France 12.3.4 Analysis of Upcoming Therapies and Impact on the Market 12.4 Market Size of Neurofibroma in Italy 12.4.1 Market Size of Neurofibroma in Italy 12.4.2 Percentage Share of Drugs Marketed for Neurofibroma in Italy 12.4.3 Market Sales of Neurofibroma by Products in Italy 12.4.4 Analysis of Upcoming Therapies and Impact on the Market 12.5 Market Size of Neurofibroma in Spain 12.5.1 Market Size of Neurofibroma in Spain 12.5.2 Percentage Share of Drugs Marketed for Neurofibroma in Spain 12.5.3 Market Sales of Neurofibroma by Products in Spain 12.5.4 Analysis of Upcoming Therapies and Impact on the Market 12.6 Market Size of Neurofibroma in United Kingdom 12.6.1 Market Size of Neurofibroma in United Kingdom 12.6.2 Percentage Share of Drugs Marketed for Neurofibroma in United Kingdom 12.6.3 Market Sales of Neurofibroma by Products in United Kingdom 12.6.4 Analysis of Upcoming Therapies and Impact on the Market 13 The Japan Market Outlook 13.1 Market Size of Neurofibroma in Japan 13.2 Percentage Share of Drugs Marketed for Neurofibroma in Japan 13.3 Market Sales of Neurofibroma by Products in Japan 13.4 Analysis of Upcoming Therapies and Impact on the Market 14 Cost Analysis of Neurofibroma 15 Generic Competition in Neurofibroma Market 16 Market Drivers 17 Market Barriers 18 Report Methodology 18.1 Methodology/Research Approach 18.2 Data Source 18.2.1 Secondary Sources 18.2.2 Primary Sources

List of Tables Table Total Prevalent/Incident Cases of the Neurofibroma in 7MM (2016-2028) Table Total Prevalent/Incident Cases of the Neurofibroma in 7MM by Countries (2016-2028) Table Prevalent/Incident Cases of the Neurofibroma in United States (2016-2028) Table Sub-Type Specific cases of Neurofibroma in the United States (2016-2028) Table Sex- Specific Cases of Neurofibroma in the United States (2016-2028) Table Diagnosed Cases of the Neurofibroma in United States (2016-2028) Table Treatable Cases of the Neurofibroma in United States (2016-2028) Table Prevalent/Incident Cases of the Neurofibroma in Germany (2016-2028) Table Sub-Type Specific cases of Neurofibroma in the Germany (2016-2028) Table Sex- Specific Cases of Neurofibroma in the Germany (2016-2028) Table Diagnosed Cases of the Neurofibroma in Germany (2016-2028) Table Treatable Cases of the Neurofibroma in Germany (2016-2028) Table Prevalent/Incident Cases of the Neurofibroma in France (2016-2028) Table Sub-Type Specific cases of Neurofibroma in the France (2016-2028) Table Sex- Specific Cases of Neurofibroma in the France (2016-2028) Table Diagnosed Cases of the Neurofibroma in France (2016-2028) Table Treatable Cases of the Neurofibroma in France (2016-2028) Table Prevalent/Incident Cases of the Neurofibroma in Italy (2016-2028) Table Sub-Type Specific cases of Neurofibroma in the Italy (2016-2028) Table Sex- Specific Cases of Neurofibroma in the Italy (2016-2028) Table Diagnosed Cases of the Neurofibroma in Italy (2016-2028) Table Treatable Cases of the Neurofibroma in Italy (2016-2028) Table Prevalent/Incident Cases of the Neurofibroma in Spain (2016-2028) Table Sub-Type Specific cases of Neurofibroma in the Spain (2016-2028) Table Sex- Specific Cases of Neurofibroma in the Spain (2016-2028) Table Diagnosed Cases of the Neurofibroma in Spain (2016-2028) Table Treatable Cases of the Neurofibroma in Spain (2016-2028) Table Prevalent/Incident Cases of the Neurofibroma in United Kingdom (2016-2028) Table Sub-Type Specific cases of Neurofibroma in the United Kingdom (2016-2028) Table Sex- Specific Cases of Neurofibroma in the United Kingdom (2016-2028) Table Diagnosed Cases of the Neurofibroma in United Kingdom (2016-2028) Table Treatable Cases of the Neurofibroma in United Kingdom (2016-2028) Table Prevalent/Incident Cases of the Neurofibroma in Japan (2016-2028) Table Sub-Type Specific cases of Neurofibroma in the Japan (2016-2028) Table Sex- Specific Cases of Neurofibroma in the Japan (2016-2028) Table Diagnosed Cases of the Neurofibroma in Japan (2016-2028) Table Treatable Cases of the Neurofibroma in Japan (2016-2028) Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Comparison of emerging drugs (Immunomodulators) under development Table Comparison of emerging drugs (other classes) under development Table Safety and Efficacy Table Product Advantages and Advantages Table Clinical Trial Description, 2018 Table Safety and Efficacy Table Product Advantages and Advantages Table Clinical Trial Description, 2018 Table Safety and Efficacy Table Product Advantages and Advantages Table Clinical Trial Description, 2018 Table Safety and Efficacy Table Product Advantages and Advantages Table Clinical Trial Description, 2018 Table Safety and Efficacy Table Product Advantages and Advantages Table Clinical Trial Description, 2018 Table7MM- Market Size of Neurofibroma in USD MM (2016-2028) Table 7MM- Market Share Neurofibroma by Therapies in USD MM (2016-2028) Table 7MM- Market Sales of Neurofibroma by Therapies in USD MM (2016-2028) Table US Market Size of Neurofibroma in USD, Million (2016-2028) Table United States-Market Share Neurofibroma by Therapies in USD MM (2016-2028) Table United States-Market Sales of Neurofibroma by Therapies in USD MM (2016-2028) Table EU5 Market Size of Neurofibroma (MS) in USD, Million (2016-2028) Table Germany Market Size of Neurofibroma in USD, Million (2016-2028) Table Germany -Market Share Neurofibroma by Therapies in USD MM (2016-2028) Table Germany -Market Sales of Neurofibroma by Therapies in USD MM (2016-2028) Table France Market Size of Neurofibroma in USD, Million (2016-2028) Table France -Market Share Neurofibroma by Therapies in USD MM (2016-2028) Table France -Market Sales of Neurofibroma by Therapies in USD MM (2016-2028) Table Italy Market Size of Neurofibroma in USD, Million (2016-2028) Table Italy -Market Share Neurofibroma by Therapies in USD MM (2016-2028) Table Italy -Market Sales of Neurofibroma by Therapies in USD MM (2016-2028) Table Spain Market Size of Neurofibroma in USD, Million (2016-2028) Table Spain -Market Share Neurofibroma by Therapies in USD MM (2016-2028) Table Spain -Market Sales of Neurofibroma by Therapies in USD MM (2016-2028) Table United Kingdom Market Size of Neurofibroma in USD, Million (2016-2028) Table United Kingdom -Market Share Neurofibroma by Therapies in USD MM (2016-2028) Table United Kingdom -Market Sales of Neurofibroma by Therapies in USD MM (2016-2028) Table Japan Market Size of Neurofibroma in USD, Million (2016-2028) Table Japan -Market Share Neurofibroma by Therapies in USD MM (2016-2028) Table Japan -Market Sales of Neurofibroma by Therapies in USD MM (2016-2028) Table Market Drivers of Neurofibroma Table Market Barriers of Neurofibroma ???